These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
218 related articles for article (PubMed ID: 33223264)
1. Development of programmable gemcitabine-GnRH pro-drugs bearing linker controllable "click" oxime bond tethers and preclinical evaluation against prostate cancer. Vrettos EI; Karampelas T; Sayyad N; Kougioumtzi A; Syed N; Crook T; Murphy C; Tamvakopoulos C; Tzakos AG Eur J Med Chem; 2021 Feb; 211():113018. PubMed ID: 33223264 [TBL] [Abstract][Full Text] [Related]
2. Development of bioactive gemcitabine-D-Lys Sayyad N; Vrettos EI; Karampelas T; Chatzigiannis CM; Spyridaki K; Liapakis G; Tamvakopoulos C; Tzakos AG Eur J Med Chem; 2019 Mar; 166():256-266. PubMed ID: 30716713 [TBL] [Abstract][Full Text] [Related]
3. GnRH-Gemcitabine conjugates for the treatment of androgen-independent prostate cancer: pharmacokinetic enhancements combined with targeted drug delivery. Karampelas T; Argyros O; Sayyad N; Spyridaki K; Pappas C; Morgan K; Kolios G; Millar RP; Liapakis G; Tzakos AG; Fokas D; Tamvakopoulos C Bioconjug Chem; 2014 Apr; 25(4):813-23. PubMed ID: 24661240 [TBL] [Abstract][Full Text] [Related]
4. Gemcitabine Based Peptide Conjugate with Improved Metabolic Properties and Dual Mode of Efficacy. Karampelas T; Skavatsou E; Argyros O; Fokas D; Tamvakopoulos C Mol Pharm; 2017 Mar; 14(3):674-685. PubMed ID: 28099809 [TBL] [Abstract][Full Text] [Related]
5. Oxime bond-linked daunorubicin-GnRH-III bioconjugates exert antitumor activity in castration-resistant prostate cancer cells via the type I GnRH receptor. Montagnani Marelli M; Manea M; Moretti RM; Marzagalli M; Limonta P Int J Oncol; 2015 Jan; 46(1):243-53. PubMed ID: 25351635 [TBL] [Abstract][Full Text] [Related]
6. Synthesis, in vitro stability, and antiproliferative effect of d-cysteine modified GnRH-doxorubicin conjugates. Li S; Zhao H; Chang X; Wang J; Zhao E; Yin Z; Mao X; Deng S; Hao T; Wang H; Yang Y J Pept Sci; 2019 Jan; 25(1):e3135. PubMed ID: 30467919 [TBL] [Abstract][Full Text] [Related]
7. Comparative in vitro biological evaluation of daunorubicin containing GnRH-I and GnRH-II conjugates developed for tumor targeting. Szabó I; Bősze S; Orbán E; Sipos É; Halmos G; Kovács M; Mező G J Pept Sci; 2015 May; 21(5):426-35. PubMed ID: 25908176 [TBL] [Abstract][Full Text] [Related]
8. Development of novel 68Ga- and 18F-labeled GnRH-I analogues with high GnRHR-targeting efficiency. Schottelius M; Berger S; Poethko T; Schwaiger M; Wester HJ Bioconjug Chem; 2008 Jun; 19(6):1256-68. PubMed ID: 18510351 [TBL] [Abstract][Full Text] [Related]
9. Evaluation of a stable gonadotropin-releasing hormone analog in mice for the treatment of endocrine disorders and prostate cancer. Katsila T; Balafas E; Liapakis G; Limonta P; Montagnani Marelli M; Gkountelias K; Tselios T; Kostomitsopoulos N; Matsoukas J; Tamvakopoulos C J Pharmacol Exp Ther; 2011 Mar; 336(3):613-23. PubMed ID: 21106905 [TBL] [Abstract][Full Text] [Related]
10. Effect of gonadotropin-releasing hormone analogs and their conjugates on gonadotropin-releasing hormone receptor--positive human cancer cell lines. Pályi I; Vincze B; Kálnay A; Turi G; Mezõ I; Teplán I; Seprõdi J; Pató J; Móra M Cancer Detect Prev; 1996; 20(2):146-52. PubMed ID: 8706040 [TBL] [Abstract][Full Text] [Related]
11. Novel Crizotinib-GnRH Conjugates Revealed the Significance of Lysosomal Trapping in GnRH-Based Drug Delivery Systems. Murányi J; Varga A; Gyulavári P; Pénzes K; Németh CE; Csala M; Pethő L; Csámpai A; Halmos G; Peták I; Vályi-Nagy I Int J Mol Sci; 2019 Nov; 20(22):. PubMed ID: 31717403 [TBL] [Abstract][Full Text] [Related]
12. Improved In Vivo Anti-Tumor and Anti-Metastatic Effect of GnRH-III-Daunorubicin Analogs on Colorectal and Breast Carcinoma Bearing Mice. Ranđelović I; Schuster S; Kapuvári B; Fossati G; Steinkühler C; Mező G; Tóvári J Int J Mol Sci; 2019 Sep; 20(19):. PubMed ID: 31557968 [TBL] [Abstract][Full Text] [Related]
13. In vitro degradation and antitumor activity of oxime bond-linked daunorubicin-GnRH-III bioconjugates and DNA-binding properties of daunorubicin-amino acid metabolites. Orbán E; Mezo G; Schlage P; Csík G; Kulić Z; Ansorge P; Fellinger E; Möller HM; Manea M Amino Acids; 2011 Jul; 41(2):469-83. PubMed ID: 20953647 [TBL] [Abstract][Full Text] [Related]
14. Paclitaxel conjugation with the analog of the gonadotropin-releasing hormone as a targeting moiety. Pribylova M; Dvorakova M; Hanusova V; Nemethova I; Skalova L; Vanek T Int J Pharm; 2011 Aug; 415(1-2):175-80. PubMed ID: 21669266 [TBL] [Abstract][Full Text] [Related]
15. Enhanced cellular uptake and in vitro antitumor activity of short-chain fatty acid acylated daunorubicin-GnRH-III bioconjugates. Hegedüs R; Manea M; Orbán E; Szabó I; Kiss E; Sipos E; Halmos G; Mező G Eur J Med Chem; 2012 Oct; 56():155-65. PubMed ID: 22967796 [TBL] [Abstract][Full Text] [Related]
16. Design, synthesis, and evaluation of a long-acting, potent analogue of gonadotropin-releasing hormone. Rahimipour S; Ben-Aroya N; Fridkin M; Koch Y J Med Chem; 2001 Oct; 44(22):3645-52. PubMed ID: 11606129 [TBL] [Abstract][Full Text] [Related]
17. Design, synthesis, and evaluation of liver-specific gemcitabine prodrugs for potential treatment of hepatitis C virus infection and hepatocellular carcinoma. Stephenson AA; Cao S; Taggart DJ; Vyavahare VP; Suo Z Eur J Med Chem; 2021 Mar; 213():113135. PubMed ID: 33454548 [TBL] [Abstract][Full Text] [Related]
18. Synthesis of Gemcitabine-Threonine Amide Prodrug Effective on Pancreatic Cancer Cells with Improved Pharmacokinetic Properties. Hong S; Fang Z; Jung HY; Yoon JH; Hong SS; Maeng HJ Molecules; 2018 Oct; 23(10):. PubMed ID: 30314360 [TBL] [Abstract][Full Text] [Related]
19. Design, characterization, and in vitro antiproliferative efficacy of gemcitabine conjugates based on carboxymethyl glucan. Ma L; Chen Y; Wang X; Xiong M; Sun Y; Zhang X; Zhao Y Bioorg Med Chem Lett; 2018 Sep; 28(17):2920-2924. PubMed ID: 30017318 [TBL] [Abstract][Full Text] [Related]
20. Cytotoxic Activity of Novel GnRH Analogs Conjugated with Mitoxantrone in Ovarian Cancer Cells. Markatos C; Biniari G; Chepurny OG; Karageorgos V; Tsakalakis N; Komontachakis G; Vlata Z; Venihaki M; Holz GG; Tselios T; Liapakis G Molecules; 2024 Aug; 29(17):. PubMed ID: 39274973 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]